Avid Bioservices Inc (CDMO)

[sulaco]

eb, thanks - the partnership will come


The anti-PS platform is indeed, unique, with a very wide applicability across many medical conditions. That's why the majority of us are here.

The "proof-of-concept" missing in Celsion's Thermadox trial, (which was a phase I, not phase 2 trial, my error) was ignored by enthusiastic CLSN longs. The phase I trial was truly terrible, as it had only 9 patients in it who actually had HCC out of a total of 24. And only 3 of these 9 had HCC larger than 3 cm. This was Thermadox's treatment indication!

Cut to Bavi. The "proof of concept" for Bavi is acknowleged throughout the scientific community. Review the cancer journals. Dig into the science. PS is a crucial marker for cancer-affected cells and is a real dampener of the immune system response if extroverted by flippase. When Bavi ties it up and neutralizes it, cell-mediated immune response and cytokines can kick back on. Cell-mediated immunity is CRUCIAL for cancer and viral affected cells. Think CD4, CD8, NK, macrophages, Il-2, interferon gamma, and many others. The cancer killers.

If the labeling error had not occurred in 9/2012, the stock would most likely be $12-15 right now. How? Well, indicators of interest from BP would be overt, ramping speculation of the stock.

Investors here know that Bavi's potential is still there and will soon enough be recognized and rewarded. But given the unusual and widely applicable nature of the platform, a partnership/buyout will most certainly take time.